Study suggests direct amino acid toxicity could account for caloric restriction benefits Jan. 28, 2020
Engineered enzyme alleviates intracellular NADH:NAD+ imbalance by targeting circulating lactate Jan. 21, 2020
Newco news Kyverna Therapeutics emerges with $25M series A and a $587M Gilead agreement Jan. 15, 2020 By Lee Landenberger Not only did newly emergent Kyverna Therapeutics Inc. burst out of the gate with a $25 million series A, but it enhanced its entrance with a deal from Gilead Sciences Inc., one of the company’s initial funders, potentially worth $587.5 million.Read More
RSS
